The independent financial analyst theScreener just lowered the general evaluation of MOMENTA PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date August 11, 2020, the c...
Two Directors at Momenta Pharmaceuticals Inc sold after exercising options/sold 59,605 shares at between 32.250USD and 32.760USD. The significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trade...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ullish Tape Despite Inconsistencies Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods. · S&P 500 Short-Term Levels. We continue to respect the bullish tape, however the S&P 500 remains in the 2855-2900 resistance zone while forming a bearish rising wedge patt...
Momenta's strategy is transitioning as the firm moves from complex generics and biosimilars into novel, branded autoimmune drugs, but its strong experience in characterizing complex proteins makes it a viable industry player and possible takeover target.Complex generics have faced higher development, manufacturing, and regulatory hurdles, which can reduce competition and pricing pressure relative to typical generic markets. However, Momenta and Sandoz's generic version of Sanofi's anticoagulant ...
Momenta uses proprietary methods to characterize the unique structural attributes and manufacturing requirements of complex drugs. The company has primarily shifted its focus toward early-stage novel products after having previously focused on characterizing complex generics and biosimilar drugs. We think the company's demonstrated expertise in complex molecules makes it a viable industry player and possible takeover target.Complex molecules face higher development, manufacturing, and regulatory...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.